Ocumension Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	804.35	417.31	246.37	158.96	56.15
Revenue Growth (YoY)	92.75%	69.38%	54.99%	183.11%	328.73%
Cost of Revenue	443.43	192.24	102	56.04	19.21
Gross Profit	360.92	225.07	144.37	102.92	36.94
Selling, General & Admin	445.39	416.91	422.4	373.79	253.81
Research & Development	75.08	113.94	123.77	184.31	169.06
Operating Expenses	521.13	531.5	546.51	558.78	422.86
Operating Income	-160.2	-306.43	-402.15	-455.86	-385.93
Interest Expense	-2.45	-2.16	-1.33	-1.79	-0.57
Interest & Investment Income	6.4	22.22	21.92	28.22	26.89
Earnings From Equity Investments	-	-	-	-	-13.33
Currency Exchange Gain (Loss)	-2.9	1.92	1.1	22.42	-13.37
Other Non Operating Income (Expenses)	-2.58	16.91	-3.36	7.31	0.54
EBT Excluding Unusual Items	-161.74	-267.55	-383.81	-399.71	-385.77
Gain (Loss) on Sale of Investments	3.27	0.29	1.16	1.25	99.84
Asset Writedown	-	-	3.18	-3.18	-
Other Unusual Items	-	-	-	-0.6	25.94
Pretax Income	-158.47	-267.26	-379.48	-402.23	-259.99
Income Tax Expense	0.35	1.02	0.31	0.41	-
Earnings From Continuing Operations	-158.82	-268.27	-379.79	-402.64	-259.99
Net Income	-158.82	-268.27	-379.79	-402.64	-259.99
Net Income to Common	-158.82	-268.27	-379.79	-402.64	-259.99
Shares Outstanding (Basic)	794	684	649	633	607
Shares Outstanding (Diluted)	794	684	649	633	607
Shares Change (YoY)	16.13%	5.33%	2.63%	4.18%	100.81%
EPS (Basic)	-0.20	-0.39	-0.59	-0.64	-0.43
EPS (Diluted)	-0.20	-0.39	-0.59	-0.64	-0.43
Free Cash Flow	-	-225.92	-258.84	-316.47	-392.22
Free Cash Flow Per Share	-	-0.33	-0.40	-0.50	-0.65
Gross Margin	44.87%	53.93%	58.60%	64.74%	65.78%
Operating Margin	-19.92%	-73.43%	-163.23%	-286.78%	-687.36%
Profit Margin	-19.74%	-64.29%	-154.16%	-253.30%	-463.06%
Free Cash Flow Margin	-	-54.14%	-105.06%	-199.09%	-698.57%
EBITDA	-83.14	-229.36	-355.76	-428.76	-376.31
EBITDA Margin	-10.34%	-54.96%	-144.40%	-269.74%	-
D&A For EBITDA	77.07	77.07	46.39	27.1	9.62
EBIT	-160.2	-306.43	-402.15	-455.86	-385.93
EBIT Margin	-19.92%	-73.43%	-163.23%	-286.78%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.